What is SLU-PP-332?
An estrogen-related-receptor (ERR) agonist (non-peptide) described as an "exercise mimetic." It copies endurance training at the gene level.
SLU-PP-332 in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
0 registered trials · 0 indexed papers · 2 human / 7 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
An estrogen-related-receptor (ERR) agonist (non-peptide) described as an "exercise mimetic." It copies endurance training at the gene level.
Mechanism (as described)
Binding ERRα changes its shape so it recruits PGC-1α. The complex switches on mitochondrial genes (cytochrome c, COX4, ATP synthase), CPT1 and fatty-acid oxidation, and maximal respiration rises. It overlaps with MOTS-c/AMPK signaling. Also described as improving cardiac efficiency, replacing leaky mitochondria (less inflammation), and having antiviral effects.
Additional points (as described)
- Shifts muscle toward fatigue-resistant type I/IIa fibers. In the liver, ERRα dampens glucose production, so both the glucose "sink" (muscle) and "source" (liver) improve.
- Mimics an endurance session at the gene level, but it's meant to be married to real exercise (the daily walk), not to replace it.
- Oral bioavailability is under 5%.
- Fat-loss trio roles: retatrutide (appetite, partitioning), MOTS-c (cell machinery), SLU-PP-332 (constant exercise signal).
More cited research
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study (2025, human observational)
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (2026, animal)
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome (2024, animal)
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function (2024, animal)
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney (2023, animal)
Conditions researched
Related compounds
- 5-Amino-1MQ
- Cardarine (GW501516, non-peptide)
- L-Carnitine
- Orforglipron (Foundayo, non-peptide)
- AICAR
- Amycretin
- Amylin (Islet Amyloid Polypeptide)
- Anamorelin (non-peptide)
- CagriSema (Cagrilintide + Semaglutide)
- Cagrilintide
FAQ
What is SLU-PP-332?
An estrogen-related-receptor (ERR) agonist (non-peptide) described as an "exercise mimetic." It copies endurance training at the gene level.
How many registered human trials study SLU-PP-332?
The PeptideWhiz trial index lists 0 registered trials for SLU-PP-332.
How much published research exists on SLU-PP-332?
By study type, PeptideWhiz counts 2 human and 7 animal studies on SLU-PP-332.
Which conditions is SLU-PP-332 researched for?
Fat loss, obesity & body recomposition.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).